Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story Anthony Mthembu | Photo Sonia Small
UFS students

The University of the Free State realises that the registration period can be stressful and frustrating to students for various reasons. 

In an effort to ensure that as many students as possible can successfully register for the 2022 academic year, the University of the Free State (UFS) has introduced a number of financial concessions. These financial concessions are specifically intended to fast-track the registration process of students who are currently awaiting confirmation of funding from the National Student Financial Aid Scheme (NSFAS).

Students with challenges regarding the application of the N+ rule

Students who have previously registered for foundation programmes and those who have continued with mainstream programmes will be allowed to register without the prerequisite of a first payment. This is on condition that they apply with the N+ rule (an added year of funding) and that their respective foundation programmes are included in the Department of Higher Education and Training (DHET)-funded list. Only students who do not have outstanding debt will qualify for this concession. 

2022 NSFAS-funded students

In addition, students whose funding has been confirmed by NSFAS for the 2022 academic year, will be permitted to register without a first payment.

Students without NSFAS 2022 funding confirmation with outstanding debt

Students awaiting NSFAS funding confirmation for 2022 will be allowed to register provisionally if their debt does not exceed R25 000.
Approval has been obtained to increase the maximum debt carried forward from 2021 from R20 000 to R25 000 to enable students to register provisionally.

Provisional registration for continuing NSFAS students 

Furthermore, continuing NSFAS students who are currently awaiting funding confirmation for the 2022 academic year, will be permitted to register provisionally. These are students
• who have been funded by NSFAS in 2021; 
• whose funding reflects on the NSFAS Bursary Agreement Report for the year 2021; and
• who have passed 50% of registered modules in 2021 or are in their final year in 2022. 
• The offer for continuing students to register provisionally also extend to those who are in the N+1 period. 

The official registration of these students will be subject to funding approval from NSFAS for the 2022 academic year. To ensure that all students are in classes on 21 February 2022, the abovementioned group of students have until 31 March 2022 to confirm their funding. 

Conditional registration for first-time entering students

With registration an overwhelming experience for first-time entering students, the UFS is also looking at concessions for these students who will start their studies at the university this year. 

The university has given first-time entering students who have applied for NSFAS funding and are awaiting confirmation, until 28 February 2022 to finalise their registration. 

Permission to finalise registration a week after the UFS registration cut-off time is granted to all South African first-time entering undergraduate students who are admitted and term-activated for 2022 NSFAS-funded academic programmes, and whose funding has not yet been confirmed. 

The amount payable for conditional registration for first-time entering students (residential and non-residential) is R500.

The UFS is hopeful that these financial concessions will assist in calming anxiety around the ongoing registration process.


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept